Challenges and perspectives of tendon-derived cell therapy for tendinopathy: from bench to bedside

Table 2 Expression of CD markers in human BMSCs, ADSCs and TDSCs

MSC	Human BMSCs	Human ADSCs	Human TDSCs
CD73	100% [54]	96.12% [55]	100% [54]
	90.4% ± 5.1% [56]	92.4% ± 4% [56]	99.9% [57]
	98.7% [58]		99.6% [59]
	99.2% [60]
CD90	100% [54]	95.54% [55]	100% [54]
	84.8% ± 4% [56]	99.53[61]	97.43% [48]
	96% [58]	99.67% [62]	94% [63]
	91.7% [60]	90.4% ± 3% [56]	99.11% [64]
			99.8% [57]
			99.8% [59]
CD105	100% [54]	95.08% [55]	100% [54]
	93.8 ± 4.6% [49]	98.76% [62]	0.1% [63]
	97.8% ± 0.6% [56]	93.8% ± 2.8% [56]	72.6 ± 22.9% [49]
	99.0% [58]		84.75% [64]
	99.6% [60]		92.6% [57]
			98.3% [59]
			Less than 90% [46]
CD44	100% [54]	100% [61]	99.82% [48]
	97.2% [58]	99.95% [65]	100% [54]
		80% [66]	93% [63]
		99.85% [62]	100% [64]
			99.9% [57]
CD34	0% [54]	0.26% [55]	0% [54]
	0.3 ± 0.4% [49]	1.05% [61]	0% [63]
	2.2% ± 0.3% [56]	0.01% [65]	0.9 ± 1.1% [49]
	0.455% [58]	3% [66]	0% [57]
	0.1% [60]	0.14% [62]
		3% ± 1.1% [56]
		0.01% [65]
CD45	0% [54]	0.11% [55]	0% [54]
	2.7% ± 0.7% [56]	1.69% [61]	0% [63]
	1.07% [58]	0.03% [65]	0.15% [48]
	0.2% [60]	1.17% [62]	0.32% [64]
		3% ± 1.2% [56]	5% [57]
		0.01% [65]
CD79a	–	–	–
CD19	1.08% [58]	0.67% [55]	–
	0.1% [60]	0.02% [65]
		2.2% [67]
CD14	0.499% [58]	0.06% [55]	12.12% [64]
CD14	0.3% [60]	0.02% [65]
CD11b	–	0.02% [65]	–
CD11b		1.3% [67]
HLA-DR	1% [54]	0.19% [55]	0% [54]
	1.5% [58]	0.27% [62]
	0.1 [60]	0.02% [65]

CD Cluster of differentiation, BMSC Bone marrow-derived stem cell, ADSC Adipose-derived stem cell, TDSC Tendon-derived stem cell, HLA-DR Human leukocyte antigen-DR isotype

ISSN: 1757-6512